Stockhead TV
Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA) CEO and managing director David Foster to get the short end of the long story on the company’s latest news.
The Australian antiviral drug development company has kicked off a phase 2b clinical trial of lead drug ISLA-101 in dengue fever with the first subjects successfully enrolled.
Dengue fever is the most prevalent mosquito-borne viral disease. According to the World Health Organization the incidence of dengue has grown dramatically around the world in recent decades, with no specific treatment.
Tune in to hear Island’s David Foster on the significance of this trial and how this brings them closer to providing a successful treatment option.
This video was developed in collaboration with Island Pharmaceuticals, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Long Shortz
Health & Biotech
Stockhead TV
